1090 redei	aı	Kegis
Drug	S	chedule
2,5-Dimethoxyamphetamine	1	
(7396).	ı	
JWH–398 (7398)2,5-Dimethoxy-4-	i	
ethylamphetamine (7399).		
3,4-Methylenedioxyamphetamine (7400).		
5-Methoxy-3,4-	I	
methylenedioxyamphetamine (7401).		
N-Hydroxy-3,4-	ı	
methylenedioxyamphetamine (7402).		
3,4-Methylenedioxy-N-	1	
ethylamphetamine (7404).		
Methylenedioxymethamphetam-	'	
ine (7405).		
4-Methoxyamphetamine (7411) 5-Methoxy-N-N-	 	
dimethyltryptamine (7431).		
Alpha-methyltryptamine (7432) Bufotenine (7433)	 	
Diethyltryptamine (7434)	i	
Dimethyltryptamine (7435)	!	
Psilocybin (7437) Psilocyn (7438)	l I	
5-Methoxy-N,N-	i	
diisopropyltryptamine (7439).		
N-Ethyl-1-phenylcyclohexylamine (7455).	ı	
N-Benzylpiperazine (7493)	I	
2C-D (7508) 2C-E (7509)	l I	
2C–H (7517)	i	
2C-I (7518)	!	
2C-C (7519) 2C-N (7521)	 	
2C-P (7524)	i	
2C-T-4 (7532)	1	
MDPV (7535) Methylone (7540)	i	
AM-694 (7694)	ŀ	
Desmorphine (9055) Dihydromorphine (9145)		
Heroin (9200)	i	
Morphine-N-oxide (9307)	1	
Normorphine (9313) Tilidine (9750)	l I	
Amphetamine (1100)	Ш	
Methamphetamine (1105) Lisdexamfetamine (1205)	II II	
Pentobarbital (2270)	ii	
Phencyclidine (7471)	II	
Phenylacetone (8501)	II II	
Codeine (9050) Dihydrocodeine (9120)	II	
Oxycodone (9143) Hydromorphone (9150)	II II	
Hydrocodone (9193)	ii	
Levomethorphan (9210)	II	
Meperidine (9230) Meperidine intermediate-B (9233)	II II	
Methadone (9250)	II	
Dextropropoxyphene, bulk (non-	Ш	
dosage forms) (9273). Morphine (9300)	Ш	
Thebaine (9333)	II	
Oxymorphone (9652) Sufentanil (9740)	II II	
Fentanyl (9801)	ii	
	<u> </u>	

The company plans to manufacture reference standards for distribution to their research and forensics customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014.

Dated: December 31, 2013.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014–00200 Filed 1–9–14; 8:45 am] BILLING CODE 4410–09–P

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

# Manufacturer of Controlled Substances Notice of Application Cody Laboratories, Inc.

Pursuant to 21 CFR 1301.33(a), this is notice that on June 12, 2013, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Dihydromorphine (9145)	1
Amphetamine (1100)	П
Methamphetamine (1105)	П
Methylphenidate (1724)	II
Amobarbital (2125)	П
Pentobarbital (2270)	П
Secobarbital (2315)	II
4-Anilino-N-phenethyl-4-piperidine	II
(ANPP) (8333).	
Phenylacetone (8501)	П
Cocaine (9041)	П
Codeine (9050)	П
Dihydrocodeine (9120)	П
Oxycodone (9143)	П
Hydromorphone (9150)	II
Diphenoxylate (9170)	II

Drug	Schedule
Ecgonine (9180)	

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 11, 2014.

Dated: December 31, 2013.

### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014–00204 Filed 1–9–14; 8:45 am]

### **DEPARTMENT OF JUSTICE**

### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration; Organix, Inc.

By Notice dated August 20, 2013, and published in the **Federal Register** on August 26, 2013, 78 FR 52801, Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Marihuana (7360)	1

The company plans to synthesize small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.